<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interleukin-6 (IL-6) exerts neuroprotective effects after <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> but can also exacerbate <z:mp ids='MP_0001845'>inflammation</z:mp> and induce neuronal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The current study investigates the role of cerebral peroxisome proliferator-activated receptor(s) gamma (PPARgamma) in the regulation of IL-6 expression in the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> cortical tissue in rats exposed to focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi>, a high-affinity PPARgamma ligand, was infused intracerebroventricularly (i.c.v.) via osmotic minipumps over a 5-day period before, during and 24 h or 48 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) for 90 min followed by reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>The expression of PPARgamma and IL-6 in cortical tissue adjacent to the ischaemic core was studied 24 h and 48 h after MCAO </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> augmented the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced upregulation of PPARgamma at both time points </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">Cerebral ischaemia</z:e> substantially increased IL-6 expression in the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> cortical tissue </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty-four hours after MCAO, the majority of microglial cells/macrophages showed an intense IL-6 immunoreactivity </plain></SENT>
<SENT sid="7" pm="."><plain>IL-6 was also localized in neurons, but the distribution of neurons positively stained for IL-6 at the border of the <z:mpath ids='MPATH_124'>infarct</z:mpath> was very <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> effectively decreased the number of IL-6-immunoreactive cells and IL-6 protein levels at 24 h but not at 48 h after MCAO </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> treatment reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improved neurological functions </plain></SENT>
<SENT sid="10" pm="."><plain>The present study demonstrates that cerebral PPARgamma suppresses the expression of IL-6 in ischaemic brain tissue during the initial phase of ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo>, in which the overproduction of IL-6 may aggravate neuronal damage, but not at later time points, when IL-6 promotes neuroprotection and inhibits neuronal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>